Home > Insider Trading > Filing (0001209191-10-046618)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1131324	Genomic Health Inc	GHDX	Services-Medical Laboratories (8071)	770552594

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1333482	J Kimberly Popovits	301 Penobscot Drive Redwood City CA 94403	President And Ceo	Yes	Yes	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership
Common Stock	Acquisiton	2010-09-14	4,000	$2.88	292,116	No	4	M	Direct
Common Stock	Disposition	2010-09-14	4,000	$15.14	288,116	No	4	S	Direct
Common Stock	Acquisiton	2010-09-15	3,734	$2.88	291,850	No	4	M	Direct
Common Stock	Disposition	2010-09-15	3,734	$15.06	288,116	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership
No	4	M	Direct
No	4	S	Direct
No	4	M	Direct
No	4	S	Direct

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Employee Stock Option (right to buy)	Disposition	2010-09-14	4,000	$0.00	4,000	$2.88
Common Stock	Employee Stock Option (right to buy)	Disposition	2010-09-15	3,734	$0.00	3,734	$2.88

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
49,348		2014-12-02	No	4	M	Direct
45,614		2014-12-02	No	4	M	Direct

Reported Non-Derivative Holdings

Sec. Name	Remaning Holdings	Nature of Ownership	Explanation
Common Stock	12,298	Indirect	By UBS for Benefit of Kimberly Popovits.
Common Stock	10,210	Indirect	Held by son.

Footnotes

The number of shares originally covered by the exercised option was 66,666 options an exercise price per share of $3.00 per share. In connection with the issuer's initial public offering on October 4, 2005, a conditional dividend was issued which increased the number of shares covered by the option by 2,062 to 69,348, reducing the effective exercise price per share to $2.88.
This sale of common stock was effected persuant to a Rule 10b5-1 sales plan adopted by the reporting person on February 10, 2010.
Reporting person undertakes to provide upon request by the Securities and Exchange Commission, the issuer or a securityholder of the issuer detailed information regarding the price and number of shares sold within the range indicated.
Represents weighted average sale price. Actual sale prices ranged from $15.01 to $15.30.
Represents weighted average sale price. Actual sale prices ranged from $15.00 to $15.17.
The option becomes exercisable as to 25% of the shares on December 2, 2004, and becomes exercisable as to 1/48th of the shares each full month thereafter.